EXEL | Exelixis, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	38.20 - 39.35
52 Week Range	20.14 - 40.02
Beta	0.29
Implied Volatility	35.76%
IV Rank	41.53%
Day's Volume	1,952,857
Average Volume	2,586,204
Shares Outstanding	275,584,000
Market Cap	10,789,113,600
Sector	Healthcare
Industry	Biotechnology
IPO Date	2000-04-17

Valuation
Profitability
Growth
Health
P/E Ratio	22.24
Forward P/E Ratio	21.94
EPS	1.76
1YR Price Target	28.50
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	1,310
Country	USA
Website	EXEL

Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

EXEL's peers: ALNY, ATNM, AUPH, AVXL, BMRN, BTAI, CPRX, TGTX, VKTX, MDGL, SGEN, HALO, XFOR, PDSB, PTCT, RETA, ICPT, KRYS, KOD, SRPT, MRTX, INOV, IONS, JAZZ, SAVA, TECH

*Chart delayed

Analyzing fundamentals for EXEL we got that it has average fundamentals where Valuation is considered to be undervalued, Profitability is very wealthy, Growth is good and Health is passable. For more detailed analysis please see EXEL Fundamentals page.

Watching at EXEL technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on EXEL Technicals page.